Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised …
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
EL Simpson, R Sinclair, S Forman, A Wollenberg…
The Lancet, 2020
thelancet.com
Background Abrocitinib, an oral selective Janus kinase 1 inhibitor, was effective and well tolerated in adults with moderate-to-severe atopic dermatitis in a phase 2b trial. We aimed to assess the efficacy and safety of abrocitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis. Methods In this multicentre, double-blind, randomised phase 3 trial (JADE MONO-1), patients (aged≥ 12 years) with moderate-to-severe atopic dermatitis (Investigator Global Assessment score≥ 3, Eczema Area and Severity Index …
